News

Zacks Investment Research on MSN3h
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
I realised I’m a ‘Mounjaro lifer’ after stopping for 8 weeks – I lost 5st but now my tummy is a ‘bottomless pit’ again
A FAT jab user has revealed that after stopping the injections for eight weeks, she has now realised she is a “Mounjaro lifer ...
Medical News Today3d
Why do some people have better weight loss results with Ozempic or Wegovy?
A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...
sharewise5d
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...
MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
CBS News6d
FDA declares end to Wegovy and Ozempic shortage - CBS News
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Stocktwits on MSN6d
Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe
Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...